facebook

Are Enhancements Included After Laser Eye Surgery at Blue Fin Vision®?

3 min read

Yes, for eligible patients, the surgical fee for enhancement is waived. Eligibility is determined by clinical criteria, applied consistently, and set out in a written policy document available at consultation.

The Three-Pathway Policy

Blue Fin Vision® operates a documented enhancement policy across three patient groups:

  • Laser refractive (LASIK, PRK, TransPRK): enhancement surgical fee waived where residual refractive error is stable, corneal tissue is adequate, and the patient is symptomatic
  • Premium intraocular lens: laser fine-tuning for residual refractive error following lens surgery, within the same eligibility framework
  • Refractive lens exchange: long-term inclusion in the refractive care framework; enhancement eligibility assessed at the standard intervals

Clinical Eligibility Criteria

Enhancement is not automatically provided following any suboptimal result. All of the following must be met:

  • Corneal topographic stability confirmed on serial mapping, no measurable change between two consecutive readings at least 6-8 weeks apart
  • Residual stromal bed depth of at least 250 microns following any further ablation
  • Refractive error within the range of laser correction and not attributable to another cause
  • Functional symptoms that the patient reports as significant

These thresholds are grounded in published safety standards and are applied consistently. They are not adjusted based on commercial considerations. ¹

Enhancement Timing

Enhancement eligibility is assessed at specific timepoints, not on request:

  • LASIK: topographic stability assessment at Month 3; enhancement if stability is confirmed
  • PRK and TransPRK: topographic stability assessment at Month 6 or later; the extended interval reflects the longer healing trajectory of surface ablation

Enhancement before topographic stability is confirmed is contraindicated regardless of how symptomatic the patient is.

Blue Fin Vision® specifically: The PRK/TransPRK enhancement timing window at Blue Fin Vision® is Month 6 at the earliest, later than some providers allow. This is a deliberate clinical position. Surface ablation healing continues for longer than LASIK, and premature enhancement in this group carries a higher risk of an unpredictable outcome than the same intervention in a LASIK patient. The conservative timing is protective, not commercial.

What Patients Should Ask Any Provider

Before proceeding with laser eye surgery anywhere, ask:

  • Is there a written enhancement policy with documented clinical eligibility criteria?
  • Under what circumstances does enhancement incur an additional fee?
  • What is the enhancement timing window for the specific procedure being offered?
  • Who performs the enhancement, the original operating surgeon or a colleague?

When things are straightforward, many clinics perform well. When they are not, that is where systems, experience and accountability matter most.

Frequently Asked Questions

Is the surgical fee waived completely or is there a partial charge?

For eligible patients, the surgical fee is waived entirely. There is no co-payment or cost-sharing. Consultation and imaging associated with enhancement eligibility assessment are included within the postoperative care framework and are not charged separately.

What if I am not eligible for enhancement because my cornea lacks sufficient tissue?

Non-eligibility based on insufficient residual tissue is a clinical determination. Where enhancement is contraindicated, the alternatives are discussed: spectacles, contact lenses, or in selected cases phakic IOL implantation. The clinical reason for non-eligibility is explained directly, with the supporting pachymetry data. No patient is declined without a clinical explanation and a documented alternative pathway.

Does the enhancement policy have a time limit?

The enhancement policy applies within the active postoperative management period. For most laser refractive patients, the policy covers the period up to and including the Month 6 review and any management that follows from it. Patients who develop late refractive regression beyond 12 months are assessed individually; the policy does not cover this scenario automatically.

References

  1. Randleman JB, Woodward M, Lynn MJ, Stulting RD. Risk assessment for ectasia after corneal refractive surgery. Ophthalmology. 2008;115(1):37-50.
  2. Albé E, Carones F, Marchini G, Tassinari G, Mastropasqua L, Rama P. Enhancement after laser in situ keratomileusis: indications and outcomes. J Cataract Refract Surg. 2009;35(10):1717-1723.
  3. Dupps WJ Jr, Wilson SE. Biomechanics and wound healing in the cornea. Exp Eye Res. 2006;83(4):709-720.
  4. Montgomery v Lanarkshire Health Board UKSC 11. Supreme Court of the United Kingdom; 2015.
  5. Hersh PS, Brint SF, Maloney RK, Durrie DS, Gordon M, Michelson MA, Thompson VM, Berkeley RB, Schein OD, Steinert RF. Photorefractive keratectomy versus laser in situ keratomileusis for moderate to high myopia. Ophthalmology. 1998;105(8):1512-1522.

Related Topics

About Blue Fin Vision®

Blue Fin Vision® is a GMC-registered, consultant-led ophthalmology clinic with CQC-regulated facilities across London, Hertfordshire, and Essex. Patient outcomes are independently audited by the National Ophthalmology Database, confirming exceptionally low complication rates.